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1. DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
Ehlers–Danlos syndrome (EDS) types I/II, III, IV, VI, VIIA/B, and
VIIC1; or according to the Villefranche nosology2: classical type
(EDS I and II), hypermobile type (EDS III), vascular type (EDS IV),
kyphoscoliotic types (EDS VIA and VIB), arthrochalasic types (EDS
VIIA and EDS VIIB), dermatosparactic type (EDS VIIC), unspecified
types, and variants.3–12
1.2 OMIM# of the disease
130000, 130010, 130020, 606408, 130050, 225400, 229200, 614170,
601776, 614557, 130060, 225410, 225320, 612350, 130070.
1.3 Name of the analysed genes or DNA/chromosome segments
COL5A1, COL5A2, TNXB, COL3A1, PLOD1, ZNF469, PRDM5,
CHST14, FKBP14, COL1A1, COL1A2, ADAMTS2, SLC39A13, B4GALT7
Disease Abbreviation
OMIM
disease Inheritance Gene
OMIM
gene
Chrom.
location
EDS, classical type EDS type I/II 130000,
130010
AD COL5A1 120215 9q34.2–
q34.3
EDS, classical type EDS type I/II 130000,
130010
AD COL5A2 120190 9q34.2–
q34.3
EDS, classical type EDS type I 130000 AD COL1A1 120150 17q21.33
EDS, hypermobile
type
EDS type III 130020 AD TNXB 600985 6p21.3
EDS due to
Tenascin-X
deficiency
EDS with
TNXB
deficiency
606408 AR TNXB 600985 6p21.3
EDS, vascular type EDS type IV 130050 AD COL3A1 120180 2q31
EDS, kyphoskoliotic
type
EDS type VIA 225400 AR PLOD1 153454 1p36.22
EDS, kyphoskoliotic
type
EDS type VIB 225400 AR ZNF469 612078 16q24
Brittle Cornea
syndrome 1
BCS 1 229200 AR ZNF469 612078 16q24
Brittle Cornea
syndrome 2
BCS 2 614170 AR PRDM5 614161 4q27
EDS, musculo-
contractural type;
D4ST1-deficient
EDS type
EDS type VIB 601776 AR CHST14 608429 15q15.1
FKBP14-deficient
EDS type
EDS type VIB 614557 AR FKBP14 614505 7p15.1
EDS, arthrochalasic
type
EDS type
VIIA
130060 AD COL1A1 120150 17q21.33
(Continued )
Disease Abbreviation
OMIM
disease Inheritance Gene
OMIM
gene
Chrom.
location
EDS, arthrochalasic
type
EDS type
VIIB
130060 AD COL1A2 120160 7q22.1
EDS, cardiac
valvular form
EDS with
COL1A2
deficiency
225320 AR COL1A2 120160 7q22.1
EDS, dermato-
sparactic type
EDS type
VIIC
225410 AR ADAMTS2 604539 5qter
EDS, progeroid form EDS with
XGPT
deficiency
130070 AR B4GALT7 604327 5q35.2–
q35.3
EDS, spondylocheiro
dysplastic form
SCD-EDS 612350 AR SLC39A13 608735 11p11.2
EDS VIB is not yet well defined. Some groups define EDS VIB as
those clinically resembling EDS VIA with normal lysyl pyridinoline/
hydroxylysyl pyridinoline (LP/HP) ratios. D4ST1-deficient EDS type,
FKBP14-deficient EDS type, EDS spondylocheiro dysplastic form and
Brittle Cornea syndrome 1 may be subsumed in this group.
1.4 OMIM# of the gene(s)
COL5A1 120215, COL5A2 120190, TNXB 600985, COL3A1 120180,
PLOD1 153454, ZNF469 612078, PRDM5 614161, CHST14 608429,
FKBP14 614505, COL1A1 120150, COL1A2 120160, ADAMTS2
604539, SLC39A13 608735, B4GALT7 604327.
1.5 Mutational spectrum
Missense mutations, nonsense mutations, splice site mutations,
insertions, deletions, and genomic rearrangements.
Presently, more than 400 mutations are known for all 14 genes
together. The majority of them (about 240) have been identified in
the COL3A1 gene.
1.6 Analytical methods
Genomic sequencing of coding regions, eventually MLPA (multiple
ligation dependent analysis) or array CGH for detection of genomic
rearrangements and large deletions.
1.7 Analytical validation
Direct sequencing of both DNA strands; verification of sequence,
MLPA and array CGH results with a second DNA extraction and a
second PCR or hybridisation, respectively.
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1.8 Estimated frequency of the disease
(incidence at birth (‘birth prevalence’) or population prevalence)
The prevalence is estimated between 1:5000 and 1:100 000 depending
on the EDS type.1,2
The autosomal recessively inherited EDS types are much rarer
compared to the dominantly inherited EDS types.
1.9 If applicable, prevalence in the ethnic group of investigated
person
Not applicable for most EDS types except for EDS type VIA, which is
most prevalent in the Middle East.
1.10 Diagnostic setting
Yes No
A. (Differential) diagnostics 2 &
B. Predictive testing 2 &
C. Risk assessment in relatives 2 &
D. Prenatal 2 &
Comment: Prenatal diagnosis is rarely requested for EDS.
2. TEST CHARACTERISTICS
Genotype or disease A: True positives
B: False positives
C: False negative
D: True negative
Present Absent
Test
Positive A B Sensitivity:
Specificity:
A/(AþC)
D/(DþB)
Negative C D Positive predictive value:
Negative predictive value:
A/(AþB)
D/(CþD)
2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
The analytical sensitivity should be nearly 100%, if a deletion/duplication
diagnostic test has been made for genes with the possibility of a genomic
rearrangement. However, regulatory mutations in non-coding regions
are supposed to be missed with exon scanning techniques, even if
these types of mutations have not yet been reported in EDS.
2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
Analytical specificity is nearly 100% because false positives may at the
most arise due to misinterpretation of rare polymorphic variants.
2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as
age or family history. In such cases a general statement should be
given, even if only a quantification can be made case by case.
Clinical sensitivity is highly dependent on the EDS type based on
fulfilment of the clinical criteria as well as of the biochemical and ultra-
structural dermal findings documented in the Villefranche nosology:1,2
 It is 50–90% for EDS type I/II (COL5A1 and COL5A2 gene),3,4 which
is genetically heterogeneous with additional, still unknown gene loci.
 It is 95% for EDS type IV (COL3A1 gene),6 EDS types VIIA and
VIIB (COL1A1 and COL1A gene, respectively) and EDS type VIA
(PLOD1 gene).7
 Sensitivity is not known in the recessively inherited clinical
entities including Brittle Cornea syndrome 1 and 2 (ZNF469
and PRDM5 gene),11 D4ST1-deficient EDS (CHST14 gene),8
FKBP14-deficient EDS,12 dermatosparactic type (ADAMTS2 gene),9
EDS progeroid form (B4GALT7 gene) and EDS spondylocheiro
dysplastic form (SLC39A13 gene).10
2.4 Clinical specificity
(proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as
age or family history. In such cases a general statement should be
given, even if only a quantification can be made case by case.
Clinical specificity is nearly 100%.
2.5 Positive clinical predictive value
(life time risk to develop the disease if the test is positive)
As all EDS types are fully penetrant, the positive clinical predictive
value is 100%. However, depending on EDS type, there may be highly
variable clinical expressivity.
2.6 Negative clinical predictive value
(probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected
person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Nearly 100%.
Index case in that family had not been tested: Five to ninty-five
percent, corresponding to the detection rate in the genes of the
different EDS types. This question arises quite often in EDS type IV if
the index patient has died already.
3. CLINICAL UTILITY
3.1 (Differential) diagnosis: The tested person is clinically affected
(To be answered if in 1.10 ‘A’ was marked)
3.1.1 Can a diagnosis be made other than through a genetic test?
No & (continue with
3.1.4)
Yes 2
Clinically 2
Imaging &
Endoscopy &
Biochemistry 2
Electrophysiology &
Other
(please describe)
Ultrastructural analysis of dermis
Biochemically Collagen electrophoresis (electrophoretic mobility of
collagen chains from cell culture), analysis of urinary
pyridinolines (abnormal ratio of LP and HP cross-links)
EDS
type Clinical
Ultrastructural
analysis
Collagen
electrophoresis
Urinary
LP/HP
I/II þ þ þ þ (þ ) 
III þ   
IV þ þ (þ ) þ 
VIA þ þ þ þ þ þ þ þ þ
VIB þ þ þ þ  
VIIA þ þ þ þ þ þ 
VIIB þ þ þ þ þ þ 
VIIC þ þ þ þ þ þ þ þ þ 
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As EDS comprises a group of different entities, each with highly variable
clinical expressivity, a primary molecular genetic analysis for differential
diagnostics is indicated only in exceptional cases with classical clinical
features and known associated mutations. Histological/ultrastructural
and biochemical/biophysical investigations should be performed
initially, if ever possible. The significance of different collagen diagnostic
approaches in different EDS types is illustrated in the table. Comparing
EDS type VIIA and VIIB, there is a marked difference in clinical severity
and in ultrastructural changes with more serious effects in EDS type
VIIA. Conversely, pN-alpha1(I)-chains are more difficult to detect
than pN-alpha2(I)-chains following collagen electrophoresis.
3.1.2 Describe the burden of alternative diagnostic methods to the
patient
Initial clinical, biochemical, and ultrastructural investigations com-
plement the molecular genetic analysis which, however, cannot
replace the former. As ultrastructural analysis and collagen electro-
phoresis require a preceding skin biopsy, refusal of the patient towards
this more invasive intervention compared with drawing a blood
sample has to be respected.
3.1.3 How is the cost effectiveness of alternative diagnostic methods
to be judged?
Unknown.
3.1.4 Will disease management be influenced by the result of a
genetic test?
No &
Yes 2
Therapy
(please
describe)
As a causal therapy is not possible, all efforts centre on
management.
Treatment with the b-blocker Celiprolol was shown in a
randomized study to be associated with a decrease in arterial
rupture in vascular EDS patients and might be the treatment of
choice for physicians aiming to prevent major complications in
patients with vascular EDS.13,14
Prognosis
(please
describe)
The genetic diagnosis essentially contributes to classification
of cases with indistinct clinical, biochemical, or ultrastructural
features. This is the basis for prognostic statements and
genetic counselling.
Management
(please
describe)
Specific supportive therapy of joints and musculature in
patients with EDS type I/II, III, VI, and VIIA/B by isotonic
training at home after physiotherapeutic instructions and under
regular controls.
After surgical interventions, wounds should be closed without
tension, preferably in two layers; deep stitches should be
applied generously and cutaneous sutures left in place for
twice as long as usual.
Regular follow-up/ control of the aorta and the large arteries
regarding dilatation, aneurysm formation, or dissection by
ultrasound or MRI – the regular intervals depend on the
dynamic of the vascular changes.
Pregnancy is dangerous for the patient with EDS type IV and for
her child because of tissue fragility leading to rupture of the
uterus or the arteries before delivery – rupture of the arteries
might occur also days post partum; hence, delivery has to be
planned in advance and has to occur in a centre; C-section
seems not to be a method to decrease such complications.
Ophthalmologic evaluation in EDS type VI and Brittle cornea
syndrome.
Early orthopaedic and surgical measures in EDS types VIIA/B.
3.2 Predictive setting: The tested person is clinically unaffected but
carries an increased risk based on family history
(To be answered if in 1.10 ‘B’ was marked)
3.2.1 Will the result of a genetic test influence lifestyle and
prevention?
Yes. If the test result is positive (please describe)
Frequent interdisciplinary follow-up, depending on EDS type
(see above).
 Specific therapeutic support of joints and musculature.
 Sport: avoid competitive and contact sport activities in EDS types
with predominant involvement of joints.
 Protection of legs, arms, and face with athletes’ pads or bandages
against traumatic skin injuries leading to ugly scars.
 Scrutiny for eventually developing aneurysms, special caution
during surgery, tight follow-up of pregnancy.
 Emergency health card noting information about the diagnosis,
possible complications, and therapeutic measures; especially in EDS
types with vascular involvement.
 Wound protection in EDS types with involvement of skin and a
tendency to haematomas.
 When skin tears do occur, irregularly frayed wound margins should
be excised and precisely adapted to allow (rapid) healing without
dystrophic scarring, which is especially important in the case of
facial wounds; numerous fine, atraumatic stitches should be used
and left in place for twice as long as usual.
If the test result is negative (please describe)
Follow-up is required in a clinically affected person, if the disease
causing mutation could not be identified. In contrast, follow-up is
dispensable in a family member, if a familial mutation has been
excluded.
3.2.2 Which options in view of lifestyle and prevention does a person
at-risk have if no genetic test has been done (please describe)?
Interdisciplinary follow-up considering all possible EDS types if the
index patient had not been analysed genetically.
Regular and specific follow-up if the index patient’s EDS type is
known.
3.3 Genetic risk assessment in family members of a diseased person
(To be answered if in 1.10 ‘C’ was marked)
3.3.1 Does the result of a genetic test resolve the genetic situation in
that family?
Yes.
3.3.2 Can a genetic test in the index patient save genetic or other
tests in family members?
No. A positive genetic test in the index patient supersedes the need to
search for further genetic causes but gives the opportunity for
targeted mutation analysis in further affected family members.
3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
Yes. Owing to clinical variability within one family and limited
presentation of full clinical features at birth or in early childhood
genetic testing enables early diagnosis and intervention.
3.4 Prenatal diagnosis
(To be answered if in 1.10 ‘D’ was marked)
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3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnostic?
Yes.
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical
consequences. Is there any evidence that a genetic test is nevertheless
useful for the patient or his/her relatives? (Please describe)
In many cases, the genetic diagnostics contribute substantially to the
classification of EDS type, if clinical, biochemical, and ultrastructural
findings are not fully informative. Recognising clinical symptoms as
belonging to the EDS and classifying them as a given EDS type is
prerequisite for clinical prognosis, specific therapy, and official accep-
tance as severe handicap. Genetic testing gives insight to inheritance
pattern and allows reasonable genetic counselling. In children with a
tendency to haematomas, a suspicion of child abuse may be alleviated
through the correct diagnosis of EDS type. The correct diagnosis will
end a diagnostic odyssey and the unwarranted suspicion of hypochon-
dria, and the appropriate patient organisation can now be approached.
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